Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors

Phase I Study of OSI-7904L in Combination With Cisplatin in Patients With Advanced Solid Tumors

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00116896

Enrollment

Registered

2005-07-01

Start date

2003-06-30

Completion date

2004-12-31

Last updated

2009-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Tumors

Brief summary

This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.

Interventions

DRUGOSI-7904L

DRUGCisplatin

Study design

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 18 years of age or older * Advanced and/or metastatic solid tumor for which no effective therapy is available * ECOG performance status 0-2 * Adequate bone marrow, hepatic and renal function

Exclusion criteria

* Patients with active or uncontrolled infections * Neurotoxicity \>= Grade 2 * Symptomatic brain metastases which are not stable

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026